Type 2 diabetes

Janssen-Cilag Ltd are the UK marketing authorisation holder.

Invokana® tablets (canagliflozin hemihydrate)

Patient Information Leaflet

Vokanamet® (canagliflozin/metformin)

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Patient Information Leaflet

We own and maintain the following websites:


Information for patients receiving Invokana

Date of preparation: November 2018 UK/CORP-18046